Literature DB >> 3020471

Enkephalinase and angiotensin converting enzyme activities in human venous and arterial plasma.

M G Spillantini, A Panconesi, P L Del Bianco, F Sicuteri.   

Abstract

Circulating opioids, particularly enkephalins, can act on specific receptors located on the neurovascular sympathetic junction. These peptides are quickly metabolized by enkephalinase and angiotensin converting enzyme (ACE). According to the parallel distribution of enkephalinase with opioid receptors in the rat brain, and its location in the vascular bed, putative differences of enkephalinase and ACE activity between arterial and venous plasma of the same subjects was researched. Venous enkephalinase activity was found to be greater than arterial activity. No arterovenous differences were present in ACE activity. The activities of both enzymes presented a positive correlation between venous and arterial plasma in the same subjects. The arterovenous difference in enkephalinase activity supports a release of the enzyme from microvessels.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3020471     DOI: 10.1016/0143-4179(86)90037-5

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  3 in total

1.  Effect on prolonged inhibition of neutral endopeptidase on cardiac hypertrophy in rats with myocardial infarction.

Authors:  C Marie; C Mossiat; C Gros; T Monteil; J Bralet
Journal:  Cardiovasc Drugs Ther       Date:  1996-11       Impact factor: 3.727

2.  Substance P-induced fibrinolysis in the forearm of healthy humans.

Authors:  M Fanciullacci; S Fedi; M Alessandri; U Pietrini
Journal:  Experientia       Date:  1993-03-15

3.  Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan.

Authors:  C Gros; A Souque; J C Schwartz; J Duchier; A Cournot; P Baumer; J M Lecomte
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.